Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
Medicago Inc. announced that it has received clearance from Health Canada to commence a Phase I human clinical trial with its H5N1 avian influenza vaccine. Enrollment of volunteers is now underway.
The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, tolerability and the immune response of the Company's H5N1 vaccine candidate in up to 48 healthy volunteers between the ages 18 to 60. Volunteers will receive two doses, injected 21 days apart of either a placebo or the influenza vaccine at doses of 5, 10 or 20 micrograms. The trial will take place at the Vaccine Evaluation Center of McGill University in Montreal, Canada, under the supervision of Dr. Brian Ward. Results of this study are expected during the fourth quarter of 2009.
"The acceptance of our Clinical Trial Application by Health Canada represents a major milestone in the company's development of novel influenza vaccines. It is a testament to the quality of our technology and demonstrates our ability to advance candidates towards human trials," said Andy Sheldon, President and CEO of Medicago. "This trial will be the first in which a plant-based vaccine will be injected into humans in Canada. We believe we have a compelling vaccine against influenza - a candidate, which at low dosage may protect against different strains of influenza that have the potential of becoming a pandemic. Combined with our rapid response and low cost manufacturing capabilities, we believe our vaccine can address an unmet gap in pandemic influenza preparedness efforts."
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Scientists Demystify an Enzyme Responsible for Drug and Food Metabolism
BioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics - Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012
Category:ZnMc_domain
Bovine_somatotropin

Scientists develop a new kind of printable, wearable insect repellent
MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors
'Mahjong' gene is key player when cancer, normal cells compete

CTech SoloVPE | Spectrophotometers | Repligen
VTT printed haemoglobin test on paper: Bioactivity presents new opportunities for paper

Hematoxylin as a killer of CALR mutant cancer cells - New therapeutic approach for the treatment of primary myelofibrosis

Single-neuron observations mark steps in Alzheimer's disease
